Stockreport

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specif [Read more]